Sign inJoin waitlistJoin the waitlist

Joseph McGuirk

Division Director, Division of Hematologic Malignancies and Cellular Therapeutics · University of Kansas School of Medicine

Credentials: · · · · ·

History

Blood and Marrow Transplant Program · University of Kansas School of Medicine
Present
University of Kansas School of Medicine
Present
University of Kansas School of Medicine
Present

Memorial Sloan Kettering Cancer Center
1997–1999
Psychiatry
Yale-New Haven Hospital
1993–1997
Yale-New Haven Hospital
1990–1993
Des Moines University College of Osteopathic Medicine
1986–1990

Research

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
New England Journal of Medicine · 2019 · 3,379 citations
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
New England Journal of Medicine · 2022 · 1,350 citations
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Journal of Clinical Oncology · 2020 · 691 citations

Sunil Abhyankar
77 papers
Siddhartha Ganguly
70 papers
NA
Nausheen Ahmed
68 papers
LS
Leyla Shune
64 papers
Muhammad Mushtaq
62 papers · 3 as a fellow
Anurag Singh
47 papers
Moazzam Shahzad
39 papers · 16 as a fellow
Omar Aljitawi
33 papers
Shebli Atrash
29 papers · 9 as a fellow
Tara Lin
29 papers
FL
Frederick Locke
24 papers
Haitham Abdelhakim
24 papers

Clinical trials

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
Principal investigator · Recruiting · Phase 1
University of Kansas Medical Center
2025–2040
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Principal investigator · Recruiting · Phase 1
University of Kansas Medical Center
2020–2028
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
Principal investigator · Completed · Phase 1
University of Kansas Medical Center
2018–2025
CAR-T Long Term Follow Up (LTFU) Study
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2015–2036